Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
November 20, 2023 Cover
Volume 101, Issue 38
As companies scramble to increase recycling capacity, they are navigating a tricky path through shifting battery chemistries and a raft of new regulations
Volume 101 |
Issue 38
Quote of the Week
What to do when language impedes science
Language barriers hold researchers back yet are rarely considered during conversations about diversity within science
Exposing a most unscrupulous journal
How one scientist uncovered identity theft, fictitious authors, and plagiarism at a nanoscience publication
-
Periodic Graphics: Hunger, digestion, and feeling full
Chemical educator and Compound Interest blogger Andy Brunning explains what’s going on in our guts before, during, and after a hearty meal
-
Feedforward, not feedback
-
NIH scientific integrity plan is fundamentally flawed, says public employee group
Public Employees for Environmental Responsibility says the proposed policy lacks clear procedures for handling scientific integrity concerns and preventing research suppression
ADVERTISEMENT
Antifungal analog offers reduced toxicity
Improved version of amphotericin B is now in clinical trial, but debate continues about its mechanism of action
